In Lausanne, Switzerland, the Afravih association has issued an urgent appeal to prevent a potential HIV rebound, citing declining testing rates and treatment interruptions amid shifting public health priorities post-pandemic. The call emphasizes the need for sustained funding, community-led outreach, and equitable access to pre-exposure prophylaxis (PrEP) and antiretroviral therapy (ART) to maintain hard-won progress against the epidemic. Without renewed vigilance, modeling suggests a possible resurgence in new infections, particularly among key populations facing barriers to care.
Why HIV Vigilance Must Continue Despite Global Progress
Although global HIV incidence has fallen by 38% since 2010, regional disparities persist, and complacency risks reversing gains. In Western Europe, including Switzerland, new diagnoses have plateaued or slightly increased in certain demographics, notably among migrants from high-burden regions and men who have sex with men (MSM) under 25. The Afravih warning aligns with UNAIDS 2023 data showing that while 86% of people living with HIV globally realize their status, only 76% are on treatment, and just 71% are virally suppressed — falling short of the 95-95-95 targets essential to conclude AIDS as a public health threat by 2030. In Switzerland, federal office of public health (FOPH) reports indicate that late diagnosis remains a concern, with approximately 20% of new HIV diagnoses presenting with advanced immune deficiency (CD4 count <200 cells/µL), increasing morbidity and transmission risk.
In Plain English: The Clinical Takeaway
- HIV remains a manageable chronic condition with treatment, but stopping medication can lead to viral rebound and immune damage.
- Regular testing and access to prevention tools like PrEP are critical, especially for those at higher risk due to behavior or geography.
- Community trust and culturally competent care are as vital as medicine in preventing outbreaks and ensuring treatment adherence.
Transmission Dynamics and Prevention Gaps in Western Europe
HIV is primarily transmitted through unprotected sexual contact, sharing of injection drug equipment, and from mother to child during pregnancy, birth, or breastfeeding — though the latter is rare in high-income settings due to universal antenatal screening and ART. The virus targets CD4+ T lymphocytes, using its envelope glycoprotein gp120 to bind to CD4 and CCR5/CXCR4 receptors, enabling viral entry and reverse transcription of its RNA genome into host DNA. Antiretroviral therapy (ART) works by inhibiting key viral enzymes: reverse transcriptase (e.g., tenofovir), protease (e.g., darunavir), and integrase (e.g., dolutegravir), reducing viral load to undetectable levels (<20 copies/mL), which prevents sexual transmission — a concept known as U=U (Undetectable = Untransmittable), confirmed by the PARTNER and HPTN 052 trials.
Despite effective tools, gaps persist. In Switzerland, PrEP uptake remains suboptimal outside urban centers, with cantonal variations in reimbursement and awareness. A 2022 Swiss HIV Cohort Study analysis found that only 15% of eligible MSM in non-urban areas were using PrEP, compared to 40% in Zurich and Geneva. Structural barriers — including stigma, lack of culturally sensitive services, and administrative hurdles for undocumented migrants — continue to limit access. The Afravih appeal specifically calls for low-threshold testing sites, peer navigator programs, and integration of HIV services into primary care and harm reduction settings.
Geo-Epidemiological Bridging: From Lausanne to Global Policy
Switzerland’s healthcare system, while universally accessible, operates through a decentralized cantonal model, meaning HIV service delivery varies by region. Unlike the NHS in the UK, which centrally commissions sexual health services, or Kaiser Permanente in the US, which integrates HIV care within large managed systems, Swiss prevention relies heavily on NGOs like Afravih and cantonal AIDS facilitate organizations. This fragmentation can create disparities: a person living with HIV in rural Valais may face longer travel times to specialty clinics than someone in Geneva, affecting retention in care. The European Centre for Disease Prevention and Control (ECDC) recommends task-shifting HIV testing to pharmacies and community organizations — a model already piloted in Vaud canton with Afravih’s involvement — to improve early detection.
Funding transparency is critical. Afravih’s advocacy is supported by grants from the Swiss HIV Cohort Study (SHCS), the Federal Office of Public Health (FOPH), and private foundations such as the Fondation privé des Genevois pour l’aide aux personnes atteintes du SIDA. The SHCS, a long-running observational study funded by the Swiss National Science Foundation (SNSF) and university hospitals, provides real-world data on treatment outcomes, resistance patterns, and comorbidities. Recent SHCS analyses show that while overall mortality among people on ART has dropped to near-population levels, disparities persist: individuals born abroad have a 1.8-fold higher risk of AIDS-defining illness, often linked to late presentation.
“We cannot afford to treat HIV as a solved problem. The tools exist, but equity in access does not. When testing drops and prevention programs lose funding, the virus finds the cracks — and it disproportionately affects those already marginalized.”
— Dr. Alexandra Calmy, Head of the HIV Unit at Geneva University Hospitals and lead investigator of the Swiss HIV Cohort Study, interviewed in Lancet HIV, 2023.
“The success of HIV treatment is one of modern medicine’s greatest achievements, but prevention must keep pace. PrEP is highly effective when taken consistently, yet real-world adherence remains a challenge — especially among young people and those facing social instability. We need innovative delivery models, like long-acting injectables, to close the gap.”
— Dr. Jared Baeten, Vice President of HIV Development at Gilead Sciences and former Professor of Global Health at the University of Washington, statement to WHO Technical Advisory Group on HIV Prevention, 2022.
Clinical Evidence Table: PrEP Efficacy and Adherence in Key Populations
| Study | Population | Intervention | Efficacy (vs. Placebo) | Key Adherence Finding |
|---|---|---|---|---|
| iPrEx (NEJM, 2010) | MSM and transgender women | Daily oral TDF/FTC | 44% overall reduction | >90% protection with >4 doses/week |
| PROUD (Lancet, 2015) | MSM in England | Daily oral TDF/FTC | 86% reduction | High adherence linked to quarterly clinic visits |
| HPTN 083 (NEJM, 2020) | MSM and TGW globally | Injectable cabotegravir every 8 weeks | 66% superior to daily TDF/FTC | 94% received ≥4 injections; discontinuation due to injection site reactions |
| DISCOVER (Lancet HIV, 2020) | MSM and TGW in US/EU | Daily TAF/FTC vs. TDF/FTC | Non-inferior efficacy | TAF/FTC associated with better bone and kidney biomarkers |
Contraindications & When to Consult a Doctor
ART is generally well-tolerated, but certain regimens require caution. Abacavir carries a risk of hypersensitivity reaction in individuals with the HLA-B*57:01 allele — mandatory screening prevents this. Dolutegravir-based regimens are contraindicated with dofetilide due to QT prolongation risk and require caution with rifampin, which lowers dolutegravir concentrations. PrEP with tenofovir disoproxil fumarate (TDF) should be avoided or monitored closely in those with chronic kidney disease (eGFR <60 mL/min/1.73m²) or osteoporosis; tenofovir alafenamide (TAF) is preferred in these cases. Anyone experiencing persistent fever, unexplained weight loss, night sweats, or oral thrush should seek testing, as these may indicate seroconversion or advanced HIV. Pregnant individuals with HIV must continue ART to prevent perinatal transmission; regimens are adjusted for safety, with efavirenz now avoided in first trimester due to neural tube defect concerns.
Mental health screening is integral to HIV care. Depression and substance use disorders are prevalent comorbidities that adversely affect adherence. Patients struggling with medication routines, experiencing side effects, or facing housing or food insecurity should consult their provider or a case manager — many Swiss cantons offer social support through AIDS help organizations.
Conclusion: Sustaining the Response Requires More Than Medicine
The Afravih appeal in Lausanne is not an alarmist cry but a pragmatic reminder: HIV control depends on consistent public health investment, community engagement, and equitable access to innovation. While scientific advances like long-acting ART and broadly neutralizing antibodies offer promise, their impact will be limited if delivery systems fail to reach those most vulnerable. As Switzerland refines its national HIV strategy, aligning with WHO’s differentiated service delivery model and strengthening cantonal coordination will be key. The goal is not merely to maintain low incidence but to drive it toward elimination — a target achievable only if no one is left behind due to geography, status, or stigma.
References
- Swiss HIV Cohort Study. (2023). https://www.shcs.ch
- European Centre for Disease Prevention and Control. (2022). HIV/AIDS surveillance in Europe 2021. https://www.ecdc.europa.eu/en/publications-data/hiv-aids-surveillance-europe-2021
- Grant, R. M., et al. (2010). Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. New England Journal of Medicine, 363(27), 2587–2599. https://doi.org/10.1056/NEJMoa1011205
- McCormack, S., et al. (2015). Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. The Lancet, 387(10013), 53–60. https://doi.org/10.1016/S0140-6736(14)61862-8
- Landovitz, R. J., et al. (2020). Cabotegravir for HIV prevention in cisgender men and transgender women. New England Journal of Medicine, 382(6), 515–526. https://doi.org/10.1056/NEJMoa1901377
